stockrow
Saturday 7 November 2026
Export NMRA’s income statement to Excel — free account
Neumora Therapeutics, Inc.
NMRA Healthcare Biotechnology
- EPS
- +30.3%
- Free cash flow
- +24.5%
- Total debt
- +172.0%
Quarter to June 2026, against a year earlier
0.49
0.00
0.00%
Follow NMRA
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 8 | 8 | 8 | 0.0% | |
| Gross margin, % | — | — | — | — | — | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | — | — | — | — | — | (237) | (131) | (236) | (244) | (237) | (213) | (0.1%) | ||||||
| EBT margin, % | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | — | — | — | — | (237) | (131) | (236) | (244) | (237) | (213) | 0.0% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | — | (1.56) | (4.81) | (3.63) | (1.53) | (1.45) | (1.23) | (1.8%) | ||||||
| Cash flow | — | — | — | — | — | (0.50) | (4.22) | (2.51) | (1.15) | (1.26) | (0.97) | +26.3% | ||||||
| Capex | — | — | — | — | — | 0.00 | (0.02) | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | — | — | (0.50) | (4.24) | (2.51) | (1.15) | (1.26) | (0.97) | +26.3% | ||||||
| Book value | — | — | — | — | — | 2.66 | 14.59 | 7.21 | 1.80 | 0.64 | 0.24 | (30.1%) | ||||||
| Shares, m | — | — | — | — | — | 152 | 27 | 65 | 159 | 163 | 173 | +1.8% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | (75) | (115) | (163) | (183) | (206) | (181) | +28.6% | |||||
| Capex | — | — | — | — | — | (1) | (1) | 0 | — | 0 | 0 | n/m | ||||||
| Free cash flow | — | — | — | — | — | (75) | (115) | (163) | (183) | (206) | (180) | +28.6% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | 392 | 364 | 453 | 284 | 158 | 97 | (20.3%) | |||||
| Net debt | — | — | — | — | — | (407) | (367) | (454) | (309) | (128) | (64) | (25.1%) | ||||||
| Shareholders’ equity | — | — | — | — | — | 405 | 397 | 469 | 287 | 104 | 45 | (28.8%) | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | 0.00 | (30.60) | (51.15) | (59.96) | (93.28) | (121.89) | (93.3) pt | |||||
| ROIC | — | — | — | — | — | 0.00 | (283.30) | (1,043.87) | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | — | 0.00 | 33.91 | (2,122.97) | (64.48) | (121.21) | (187.11) | (121.2) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | 110 | 124 | 110 | 96 | — | (4.4%) | |||||
| Revenue/emp, $m | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Neumora Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| BDTX Black Diamond Therapeutics, Inc. | $95.4M | — (loss-making) | — (loss-making) | — | n/m | +12.91% (above 0%: growing) | 100.00% | 0.00% | Compare |
| LENZ LENZ Therapeutics, Inc. | $94.6M | — (loss-making) | — (loss-making) | −72.93% (below 0%: shrinking) | n/m | −147.16% (below 0%: shrinking) | 86.58% | (972.75%) | Compare |
| VANI Vivani Medical, Inc. | $93.8M | — (loss-making) | — (loss-making) | −71.87% (below 0%: shrinking) | n/m | +0.39% (above 0%: growing) | 0.00% | 0.00% | Compare |
| VXRT VAXART, INC. | $92.4M | 2.8× | — (loss-making) | −85.33% (below 0%: shrinking) | n/m | −57.23% (below 0%: shrinking) | 100.00% | (162.74%) | Compare |
| NMRA Neumora Therapeutics, Inc. | $91.5M | — (loss-making) | — | — | n/m | +24.45% (above 0%: growing) | 0.00% | 0.00% | |
| ICCC ImmuCell Corporation | $90.4M | 117× | — (loss-making) | +11.50% (above 0%: growing) | +233.33% (above 0%: growing) | +54.86% (above 0%: growing) | 33.92% | 26.93% | Compare |
| SEER Seer, Inc. | $90.3M | — (loss-making) | — (loss-making) | −23.43% (below 0%: shrinking) | n/m | +36.73% (above 0%: growing) | 48.55% | (542.91%) | Compare |
| RTSN Retension Pharmaceuticals, Inc. | $89.3M | — | — | — | — | — | — | — | Compare |
| CBUS Cibus, Inc. | $87.1M | — (loss-making) | — (loss-making) | +6.54% (above 0%: growing) | n/m | +31.62% (above 0%: growing) | 100.00% | (1,300.30%) | Compare |
| Median of peers | $91.4M | — | — | −47.65% | — | +12.91% | 86.58% | (162.74%) |
Pay and ownership Proxy statement filed 17 April 2026
Ownership
Directors and executive officers, together
25.90%
Amgen Inc.
19.40%
Kristina Burow
18.70%
Entities Affiliated with ARCH Venture Partners
18.60%
Paul L. Berns
5.30%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement